Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.
Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.